logo-loader
HealthPharma & Biotech

Broad label approval is 'best possible outcome' for Shield Therapeutics' Feraccru

Proactive Research analyst Emma Ulker discusses what she describes as the best possible outcome for its lead drug Feraccru. 

The US Food & Drug Administration (FDA) has approved the treatment for a broad label to treat iron deficiency (ID) in adults, addressing a population many times wider than the iron deficiency anaemia (IDA) indications included in the submission data.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Rockfire Resources' David Price discusses Brigalow Alluvial...

Rockfire Resources PLC's (LON:ROCK) David Price tells Proactive London's Andrew Scott they've been getting a better understanding of an alluvial gold deposit next one of their main assets in Queensland. Calculations made in 1986 on an area known as Brigalow Alluvial Goldfield has suggested...

2 days, 18 hours ago

2 min read